Le Lézard
Classified in: Health, Science and technology

Protagonist Therapeutics Reports Granting of Inducement Award


NEWARK, Calif., Feb. 26, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today reported that on  February 26, 2021, it issued an inducement award to Jami Taylor, the Company's recently hired Vice President, Corporate Affairs, in accordance with the terms of Ms. Taylor's employment offer letter. The award was granted under the Protagonist Therapeutics Amended and Restated Inducement Plan, which was adopted May 29, 2018, and amended February 18, 2020.

The inducement award consists of an option to purchase 50,000 shares of Protagonist Therapeutics common stock and has a ten-year term. The exercise price of the option is $23.57, which was the per-share closing price of Protagonist Therapeutics common stock on the Nasdaq Global Market on February 26, 2021. The shares subject to the option vest over a four-year period, with 25 percent of the shares subject to the option vesting on the first anniversary of Ms. Taylor's of hire and the remainder vesting in equal monthly installments over three years thereafter. The award was approved by the compensation committee of the Company's board of directors and was granted as a material inducement to Ms. Taylor entering into employment with the Company in accordance with Nasdaq Marketplace Rule 5635(c)(4).

About Protagonist Therapeutics, Inc.

Protagonist Therapeutics is a clinical stage biopharmaceutical company with multiple peptide-based new chemical entities in different stages of development. PTG-300 is an injectable hepcidin mimetic in a Phase 2 proof-of-concept clinical trial for polycythemia vera, and a separate Phase 2 clinical study for hereditary hemochromatosis. PTG-200 is an orally delivered, gut-restricted, interleukin-23 receptor specific antagonist peptide in a Phase 2 clinical trial for Crohn's disease. Two additional oral peptide interleukin-23 receptor antagonist candidates are in development: PN-235, in a Phase 1 study, and PN-232, in the late preclinical stage. PN-943 is an orally delivered, gut-restricted alpha-4-beta-7 integrin specific antagonist peptide in a Phase 2 study for the potential treatment of inflammatory bowel disease, with ulcerative colitis as the initial targeted indication. The Company utilizes a proprietary technology platform to discover and develop novel peptide-based therapeutics to address significant unmet medical needs and transform existing treatment paradigms.

Protagonist is headquartered in Newark, California. For further information, please visit www.protagonist-inc.com

SOURCE Protagonist Therapeutics, Inc.


These press releases may also interest you

at 10:05
InfluxData, creator of the leading time series database InfluxDB, today announced three leadership promotions ? Barbara Nelson to Vice President of Applications, Rick Spencer to Vice President of Platform and Marc Kaplan to Vice President of...

at 10:05
SoundHound Inc., the leading innovator of voice AI and conversational intelligence technologies, has announced the expansion of its Houndify Voice AI platform to 22 languages?covering a majority of the world's common languages. Now, developers...

at 10:05
Terminus, the leading go-to-market platform, today announced its next-generation API integration with LinkedIn Marketing Solutions. The new and extended capabilities enable mutual customers to easily extend their Terminus Account Lists onto...

at 10:05
Scientists at City of Hope, a world-renowned independent research and treatment center for cancer and diabetes, have developed a novel, noninvasive liquid biopsy test for detecting lymph node metastasis in individuals with high-risk T1 colorectal...

at 10:05
Copysmith, a startup that uses artificial intelligence (AI) for creative content generation, today announced a $10 million investment through a partnership with Harmony Ventures Labs (HVL) and funds advised by PSG. The funding is intended to help...

at 10:05
In response to the global pandemic, corporate finance priorities have shifted significantly for 2021, according to new Key Issues research from The Hackett Group, Inc. . Becoming a strategic advisor is now the top priority, followed by the need to...



News published on 26 february 2021 at 18:20 and distributed by: